tirzepatide trial sign up Cardiovascular outcomes of semaglutide and for patients with type 2 diabetes in clinical practice At a glance factsheet: Tirzepatide

Key Findings: No significant difference in overall adverse events between the two drugs Tirzepatide increased treatment discontinuation by 32% a crucial real-world consideration Better glycemic control (HbA1c targets) with tirzepatide, especially in early-stage disease Efficacy vs tolerability trade-off remains central to treatment decisions Clinical Insight: While tirzepatide offers strong metabolic benefits, our analysis highlights a critical reality: A treatment is only effective if patients can tolerate and continue it

Epileptic seizures and epilepsy: definitions proposed by the international league against epilepsy (ILAE) and the International Bureau for Epilepsy (IBE)

doi: 10.1007/s40263-015-0301-8 [DOI] [PubMed] [Google Scholar] 24

doi: 10.3389/fendo.2021.742873

Refrigerate upon arrival

Hydration Is Foundational To GLP-1 Success Hydration is not optional in a GLP-1 program